TITLE

Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Prednisone (EPOCH) for Treatment of Lymphomas

AUTHOR(S)
Leu, Lily; Solimando, Dominic A.; Waddell, J. Aubrey
PUB. DATE
November 2007
SOURCE
Hospital Pharmacy;Nov2007, Vol. 42 Issue 11, p1006
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article covers issues related to preparation, dispensing and administration of cancer chemotherapy and agents used to treat malignant diseases. Suggestions for acute emesis prophylaxis include a serotonin antagonist and a corticosteroid. Adequate hydration is needed for patients receiving cyclophosphamide to reduce the risk of hemorrhagic cystitis. An antiemetic prescription should be given to patients to treat breakthrough nausea.
ACCESSION #
27587061

 

Related Articles

  • Optimizing Emetic Control in Children Receiving Antineoplastic Therapy. Dupuis, L. Lee; Nathan, Paul C. // Pediatric Drugs;2010, Vol. 12 Issue 1, p51 

    Existing guidelines for the prevention of antineoplastic chemotherapy-induced nausea and vomiting (CINV) in children are constrained by the lack of robust evidence. Current guidelines recommend the use of a serotonin 5-HT3 receptor antagonist plus a corticosteroid to prevent acute CINV....

  • Oncology Patient Evidence-Based Notes (OPEN): Antiemetics for Chemotherapy-Induced Nausea and Vomiting. Cope, Diane // Clinical Journal of Oncology Nursing;Jul/Aug2003, Vol. 7 Issue 4, p461 

    Focuses on antiemetic agents which will prevent or reduce acute and delayed nausea and emesis associated with chemotherapy administration. Action taken by the American Society of Clinical Oncology to create evidence-based clinical practice guidelines for the use of antiemetics; Dosage of...

  • Fosaprepitant and aprepitant: an update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomiting. Langford, Patrick; Chrisp, Paul // Core Evidence;2010, Vol. 5 Issue 1, p77 

    Introduction: The selective neurokinin-1 receptor antagonist aprepitant is effective in the treatment of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with both moderately and highly emetogenic chemotherapy. Fosaprepitant has been developed as an intravenous...

  • Stratified administration of serotonin 5-HT3 receptor antagonists (setrons) for chemotherapy-induced emesis. Economic implications. Sanchez, L.A.; Holdsworth, M.; Bartel, S.B. // PharmacoEconomics;2000, Vol. 18 Issue 6, p533 

    The serotonin 5-HT3 receptor antagonists or 'setrons' have become the standard of care for the prevention of chemotherapy-induced emesis (CIE) and are first-line therapy for acute CIE in healthcare organisations worldwide. However, their superior efficacy versus standard antiemetics comes at a...

  • Comparing Different Antiemetic Regimens for Chemotherapy Induced Nausea and Vomiting. Ghosh, Sayantani; Dey, Saugat // International Journal of Collaborative Research on Internal Medi;May2010, Vol. 2 Issue 5, p142 

    Background: Chemotherapy Induced Nausea and Vomiting (CINV) is a major problem for all cancer patients. 5-hydroxytryptamine 3 (5-HT3)-receptor antagonists or serotonin antagonists used along with dexamethasone is the most widely used antiemetic regimen in chemotherapy. But the best drug of the...

  • ondansetron.  // Royal Society of Medicine: Medicines;2002, p409 

    The article presents information on ondansetron which is an anti-emetic and antinauseant which gives relief from nausea and vomiting, especially in patients receiving chemotherapy and where other drugs are ineffective. It acts as a serotonin receptor antagonist, blocking the action of the...

  • Transdermal Granisetron. Duggan, Sean T.; Curran, Monique P. // Drugs;2009, Vol. 69 Issue 18, p2597 

    Granisetron is a highly selective serotonin 5-HT3 receptor antagonist for the prevention of chemotherapy- induced nausea and vomiting. The transdermal granisetron system delivers continuous granisetron (3.1mg/day) into the systemic circulation (via passive diffusion) for up to 7 days. In a large...

  • The Next Generation of Chemotherapy- Induced Nausea and Vomiting Prevention and Control:A New 5-HT 3 Antagonist Arrives. Rittenberg, Cynthia N. // Clinical Journal of Oncology Nursing;Jun2004, Vol. 8 Issue 3, p307 

    First-generation serotonin receptor antagonists greatly improved the control of chemotherapy-induced nausea and vomiting (CINV) during the 1990s. A new class of agents, neurokinin-1 receptor antagonists, was introduced in March 2003 and produced even greater control of CINV when used in...

  • A Phase II Study to Evaluate the Efficacy of Ramosetron, Aprepitant, and Dexamethasone in Preventing Cisplatin-Induced Nausea and Vomiting in Chemotherapy-Naïve Cancer Patients. Geundoo Jang; Hun Ho Song; Keon Uk Park; Hyeong Su Kim; Dae Ro Choi; Jung Hye Kwon; Ho Young Kim; Boram Han; Jung Han Kim; Joo Young Jung; Hyo Jung Kim; Dae Young Zang // Cancer Research & Treatment;Sep2013, Vol. 45 Issue 3, p172 

    Purpose: Combination therapy with aprepitant, serotonin receptor antagonist, and steroids improves the complete response rate of both acute and delayed chemotherapyinduced nausea and vomiting (CINV). However, it is not known whether ramosetron is suitable for administration in combination with...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics